Company / Working Capital
Immunovant, Inc. Working Capital History
FY2020-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$617.2M
FY2024
5-year range
$93.8M / $617.2M
FY2020-FY2024
Trend
+70.9%
vs FY2023
Sector context
#73 of 215
Health Care
What the data says
At $617M, Immunovant, Inc.'s working capital ranks #73 of 215 in the Health Care sector. Improved from $468M to $617M over the past 2 years.
Based on SEC 10-K filings.
$617M in FY2024 with a 3-year CAGR of +16.5%.
Improved from $468M to $617M over the past 2 years.
Health Care sector context is included.
Working Capital over time
Growth rates
- 3-Year CAGR
- +16.5%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#73 of 215 in Health CareTop 34% of 215This company $617.2M Sector average $957.8M
▼
-35.6% below sector average
Key checks
Key Insights
- 3-year CAGR of +16.5%, indicating consistent growth.
- In FY2024, working capital increased 70.9% year-over-year.
- Ranks #73 out of 215 companies in the Health Care sector.
- Lowest working capital in the period was in FY2020.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $617.2M | +70.9% |
| FY2023 | $361.0M | -22.9% |
| FY2022 | $468.4M | +20.0% |
| FY2021 | $390.2M | +316.2% |
| FY2020 | $93.8M | - |
| FY2019 | - | - |
| FY2018 | - | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026